Dyne Therapeutics develops nucleic acid therapies using its proprietary FORCE™ platform to enhance muscle tissue delivery for patients with genetically driven muscle diseases. The company focuses on creating targeted treatments that aim to halt or reverse the progression of serious muscle disorders.
Funding
$325.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many genetically driven muscle diseases lack effective treatments due to the difficulty of delivering therapeutic molecules specifically to muscle tissue. Traditional drug delivery methods often result in limited efficacy and systemic side effects, hindering the development of targeted therapies for these debilitating conditions.
Solution
Dyne Therapeutics is developing nucleic acid therapies for genetically driven muscle diseases, utilizing its proprietary FORCE™ platform to enhance drug delivery to muscle tissue. The FORCE™ platform overcomes limitations of muscle tissue delivery, enabling the development of targeted oligonucleotide therapeutics. These therapies aim to halt or reverse the progression of serious muscle disorders by directly addressing the underlying genetic causes. Dyne is building a portfolio of therapies focused on transforming the lives of individuals affected by these diseases.
Target Audience
The primary target audience includes patients living with genetically driven muscle diseases, their families, and caregivers.
Features
- Proprietary FORCE™ platform for enhanced delivery of oligonucleotides to muscle tissue
- Development of targeted therapies for genetically driven muscle diseases
- Focus on halting or reversing disease progression
- Broad portfolio of therapies in development